Workflow
HECHI CHEMICAL(000953)
icon
Search documents
河化股份:银亿控股100%股权转让给北京胜顶或其指定方
Xin Lang Cai Jing· 2025-08-06 13:26
河化股份公告,银亿控股之全体股东拟将所持银亿控股100%股权转让给北京胜顶或北京胜顶指定方。 截止2025年8月6日,银亿控股持有公司8700万股股份,占公司总股本的23.76%。本次交易若最终得以 实施,公司的控股股东仍为银亿控股,公司的实际控制人将发生变更。交易收购总价为人民币6.92亿 元,包括现金交易款3.37亿元及承接债务3.55亿元。 ...
河化股份:公司高度重视股东回报
(编辑 王雪儿) 证券日报网讯 河化股份8月5日在互动平台回答投资者提问时表示,公司高度重视股东回报,截至2024 年12月31日公司合并报表、母公司报表中累计未分配利润均为负值,不满足实施现金分红的条件,公司 2024年度不进行利润分配符合《中华人民共和国公司法》等法律法规及《广西河池化工股份有限公司章 程》的相关规定,符合公司实际经营发展情况,具体详见公司于2025年4月30日在指定信息披露媒体披 露的《关于2024年度利润分配议案专项说明的公告》(公告编号:2025-016)。 ...
财达证券晨会纪要-20250804
Caida Securities· 2025-08-04 03:57
Summary of Key Points Core Insights - The report highlights significant stock suspensions due to control change plans in various companies, indicating potential shifts in management and strategic direction [1][2][3] - The report also notes the listing of new financial instruments, such as the Guangdong JianKe stock, which may present investment opportunities for market participants [1] Company and Industry Analysis - The report mentions the suspension of the Invesco Great Wall S&P Consumer Select ETF (QDII) to protect investor interests, reflecting the regulatory environment's impact on investment products [1] - Several companies, including Hehua Co. and Black Sesame, are undergoing control changes, which could lead to strategic realignments and affect their market performance [1][2] - The report lists multiple financial instruments that have been suspended for various reasons, including continuous losses and management decisions, indicating a cautious approach from investors [4][5][6]
广西河池化工股份有限公司 关于筹划控制权变更事项进展暨继续停牌的公告
Group 1 - The company, Guangxi Hechi Chemical Co., Ltd., is undergoing a potential change in control due to the planned transfer of 23.76% equity held by its controlling shareholder, Ningbo Yinyi Holdings Co., Ltd. [3] - The stock of the company (stock abbreviation: Hehua Co., stock code: 000953) has been suspended from trading since July 31, 2025, with an expected suspension period of no more than 2 trading days [3][4] - As of August 1, 2025, the company announced that the parties involved are actively advancing the transaction, but no formal agreement has been signed yet, leading to an extension of the trading suspension until at least August 4, 2025 [4] Group 2 - The company emphasizes the importance of fair information disclosure to protect investor interests and avoid abnormal stock price fluctuations during this uncertain period [3][4] - The company will continue to fulfill its information disclosure obligations according to relevant laws and regulations during the suspension period and will announce any developments promptly [4]
河化股份: 关于筹划控制权变更事项进展暨继续停牌的公告
Zheng Quan Zhi Xing· 2025-08-01 16:35
证券代码:000953 证券简称:河化股份 公告编号:2025-027 广西河池化工股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和 完整,没有虚假记载、误导性陈述或者重大遗漏。 简称:河化股份,股票代码:000953)自2025年8月4日(星期一)上午 开市起继续停牌,预计停牌时间不超过3个交易日。 定性,敬请广大投资者关注后续公告,注意投资风险。 一、停牌事项 简称"银亿控股")的通知,其正在筹划转让其所持有的公司 23.76% 的股权事宜,该事项可能导致公司控制权发生变更。目前各方尚未签 署相关正式交易协议,正就相关事项进行进一步论证和磋商,具体情 况以各方签订的相关正式交易协议为准。 停牌期间,公司将根据事项进展情况,严格按照有关法律法规的 规定和要求履行信息披露义务。待上述事项确定后,公司将及时发布 相关公告并申请复牌。 公司指定信息披露媒体为《中国证券报》《证券时报》及巨潮资 讯网(www.cninfo.com.cn),公司所有信息均以在上述指定信息披露媒 体刊登的公告为准。敬请广大投资者关注后续公告,并注意投资风险。 特此公告。 特别提示: 鉴于该事项正在筹划中,尚未签署协议, ...
河化股份(000953.SZ):股票继续停牌,预计停牌时间不超过3个交易日
Ge Long Hui A P P· 2025-08-01 12:02
格隆汇8月1日丨河化股份(000953.SZ)公布,2025年8月1日,公司收到银亿控股通知,相关各方正在积 极推进本次交易的各项工作,交易对方系属化工材料行业,但交易各方尚未签署正式协议,整体交易方 案仍在积极协商中,公司预计无法在2025年8月4日(星期一)上午开市起复牌。根据《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第6号——停复牌》等相关规定,经向深圳证 券交易所申请,公司股票自2025年8月4日(星期一)开市起继续停牌,预计停牌时间不超过3个交易 日。 ...
河化股份(000953) - 关于筹划控制权变更事项进展暨继续停牌的公告
2025-08-01 11:15
证券代码:000953 证券简称:河化股份 公告编号:2025-027 广西河池化工股份有限公司 关于筹划控制权变更事项进展暨继续停牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和 完整,没有虚假记载、误导性陈述或者重大遗漏。 特别提示: 1、广西河池化工股份有限公司(以下简称"公司")股票(股票 简称:河化股份,股票代码:000953)自2025年8月4日(星期一)上午 开市起继续停牌,预计停牌时间不超过3个交易日。 2、本次公司控制权变更事项目前处于商谈阶段,结果尚存在不确 定性,敬请广大投资者关注后续公告,注意投资风险。 一、停牌事项 2025年7月30日,公司收到控股股东宁波银亿控股有限公司(以下 简称"银亿控股")的通知,其正在筹划转让其所持有的公司 23.76% 的股权事宜,该事项可能导致公司控制权发生变更。目前各方尚未签 署相关正式交易协议,正就相关事项进行进一步论证和磋商,具体情 况以各方签订的相关正式交易协议为准。 鉴于该事项正在筹划中,尚未签署协议,具有较大不确定性。为 保证公平信息披露,维护投资者利益,避免公司股价异常波动,经公 司向深圳证券交易所申请,公司股票(股票简称: ...
河化股份:控股股东银亿控股正在筹划转让其持有的公司23.76%的股权 股票继续停牌
news flash· 2025-08-01 11:11
河化股份(000953)公告,公司股票自2025年8月4日(星期一)上午开市起继续停牌,预计停牌时间不超 过3个交易日。此前,公司控股股东银亿控股正在筹划转让其持有的公司23.76%的股权,该事项可能导 致公司控制权发生变更。目前各方尚未签署相关正式交易协议,正就相关事项进行进一步论证和磋商。 ...
原料药上市公司董秘PK:新天地谢雨珊、东亚药业周剑波、欧康医药曹永强年薪不足20万远低于行业均值
Xin Lang Cai Jing· 2025-08-01 06:12
Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]
原料药上市公司董秘PK:新天地谢雨珊、东亚药业周剑波、欧康医药曹永强年薪不足20万 远低于行业均值
Xin Lang Zheng Quan· 2025-08-01 04:55
Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]